Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

NKGen Biotech’s SNK01 ‘natural killer’ cell therapy for Alzheimer’s gets FDA nod for clinical trial

By Brian Buntz | October 27, 2023

NKGenSanta Ana, California–based NKGen Biotech has received FDA clearance to begin a phase 1/2a trial for their “natural killer” cell therapy, SNK01, designed to treat Alzheimer’s Disease. The autologous, non-genetically modified natural killer (NK) cell therapy involves extracting a patient’s own cells through a blood draw, and then processing them to enhance their natural abilities in a laboratory setting before reinfusing them into the patient’s body.

NKGEN Biotech modifies NK cells to improve their cytotoxicity and their activating receptor expression, which helps them to identify and engage with target cells. This process imparts the NK cells with the ability to target and combat the specific cells associated with Alzheimer’s.

Early data are promising

Data from a phase 1, 3 + 3 dose-escalation trial found SNK01 to be well-tolerated. The drug candidate appeared to cross the blood-brain barrier to help reduce proteins and neuroinflammation in a dose-dependent manner. Clinical investigators did not observe any related serious adverse effects. Additionally, they reported no dose-limiting toxicities, while observing positive changes in cognitive function and cerebrospinal fluid biomarkers.

Traditional Alzheimer’s treatments focus mainly on mitigating symptoms rather than halting or reversing disease progression. Common treatments include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, as well as glutamate regulators like memantine.

Growing success in treating Alzheimer’s

In recent years, drug developers have had increasing success with monoclonal antibodies for Alzheimer’s. One of the most notable is lecanemab, which scored traditional FDA approval in July. It won accelerated approval near the beginning of the drug. In clinical trials, lecanemab has shown promise in reducing cognitive decline in patients with mild cognitive impairment resulting from Alzheimer’s, with a 27% reduction in cognitive decline over 18 months observed in phase 3 clinical trials. Another promising monoclonal antibody is donanemab, which could potentially win FDA approval by the year’s end. In the phase 3 TRAILBLAZER-ALZ 2 study, nearly half (47%) of the participants on donanemab had no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB). Donanemab treatment also resulted in 40% less decline in the ability to perform activities of daily living.

NKGen Biotech’s SNK01 therapy, like J&J’s ACI-35.030 Alzheimer’s-focused active immunotherapy, intend to coax the body into combating the underlying causes of Alzheimer’s disease. While the monoclonal antibodies target amyloid plaques in the brain, NKGen’s SNK01 therapy taps the body’s natural killer cells to combat Alzheimer’s disease. J&J’s ACI-35.030 vaccine targets the tau protein, aiming to reduce its spread in the brain.

NKGen Biotech’s NK cell therapy candidate, SNK01, is undergoing development for both oncology and neurodegeneration. The company’s SNK02 (allogeneic NK cell therapy) is also in phase 1.


Filed Under: Neurological Disease
Tagged With: Alzheimer's disease, clinical trial, FDA clearance, monoclonal antibodies, natural killer cell therapy, NKGen Biotech, SNK01
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
Randy Bateman, MD, talks with research technician Olatayo Ajenifuja about Alzheimer’s Disease research in his lab on January 4, 2024, in the Neuroscience Research Building. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Discontinued Alzheimer’s drug shows surprising long-term promise in genetic form of the disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE